These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26910127)

  • 1. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Agúndez JA
    Expert Opin Drug Metab Toxicol; 2016; 12(4):433-48. PubMed ID: 26910127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic considerations in the treatment of Parkinson's disease.
    Kurzawski M; Białecka M; Droździk M
    Neurodegener Dis Manag; 2015; 5(1):27-35. PubMed ID: 25711452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
    Arbouw ME; van Vugt JP; Egberts TC; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):159-76. PubMed ID: 17286539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
    Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
    Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacogenetics in Parkinson's disease treatment].
    Białecka M; Kłodowska-Duda G; Kurzawski M; Droździk M
    Neurol Neurochir Pol; 2008; 42(2):131-8. PubMed ID: 18512170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and pharmacogenomic biomarkers of Parkinson's disease.
    Alonso-Navarro H; Jimenez-Jimenez FJ; Garcia-Martin E; Agundez JA
    Curr Drug Metab; 2014 Feb; 15(2):129-81. PubMed ID: 24694231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of drug response in Parkinson's disease.
    Džoljić E; Novaković I; Krajinovic M; Grbatinić I; Kostić V
    Int J Neurosci; 2015; 125(9):635-44. PubMed ID: 25226559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.
    Kraemmer J; Smith K; Weintraub D; Guillemot V; Nalls MA; Cormier-Dequaire F; Moszer I; Brice A; Singleton AB; Corvol JC
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1106-11. PubMed ID: 27076492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
    Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetics of Parkinson's disease.
    Mullin S; Schapira A
    Br Med Bull; 2015 Jun; 114(1):39-52. PubMed ID: 25995343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population.
    Chung SJ; Jung Y; Hong M; Kim MJ; You S; Kim YJ; Kim J; Song K
    Neurobiol Aging; 2013 Nov; 34(11):2695.e1-7. PubMed ID: 23820587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 15. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
    Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
    Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Searching genetic risk factors for sporadic Parkinson's disease].
    Mizuta I; Toda T
    Nihon Rinsho; 2004 Sep; 62(9):1635-40. PubMed ID: 15462377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients.
    Cha PC; Satake W; Ando-Kanagawa Y; Yamamoto K; Murata M; Toda T
    J Hum Genet; 2020 Aug; 65(8):693-704. PubMed ID: 32355309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease. Psychological disorders: striking a balance in order to optimise antiparkinsonian treatment.
    Prescrire Int; 2011 Oct; 20(120):242-5. PubMed ID: 21970092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward identification of susceptibility genes for sporadic Parkinson's disease.
    Toda T; Momose Y; Murata M; Tamiya G; Yamamoto M; Hattori N; Inoko H
    J Neurol; 2003 Oct; 250 Suppl 3():III40-3. PubMed ID: 14579123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the genetics of Parkinson's disease.
    Rosner S; Giladi N; Orr-Urtreger A
    Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.